Sun Pharma Advanced Research Company Limited is a pharmaceutical research and development company focused on developing innovative drugs and drug-delivery technologies. Its long-term potential depends on successful clinical development, regulatory approvals and commercialization of its pipeline. New product approvals and partnerships can create significant opportunities. R&D expenditure, clinical outcomes, regulatory risk, commercialization timelines and competition remain important factors.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹6,006 cr | ₹1,910 cr | ₹1,584 cr | 3.8 | 48.81 | 4.49 | 277.4% | 751.5% | 163.9% | 0.42 | ₹-262 cr | 4.2 | 1.76 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 40 | -21 | -0.64 | — | +314.1% | -52.0% |
| Mar 2026 | 1,853 | 1,761 | 54.27 | turnaround | +6715.8% | 95.0% |
| Dec 2025 | 8 | -80 | -2.48 | — | -43.3% | -951.7% |
| Sep 2025 | 8 | -76 | -2.34 | — | -38.9% | -965.0% |
| Jun 2025 | 10 | -52 | -1.60 | — | -42.6% | -538.1% |
| Mar 2025 | 27 | -60 | -1.84 | — | +64.2% | -219.8% |
| Dec 2024 | 15 | -80 | -2.45 | — | +7.6% | -533.3% |
| Sep 2024 | 13 | -107 | -3.31 | — | -39.3% | -834.6% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✓ Pass |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✗ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 108.71 ✗ Within 25% of the 52-week high · high 277.57 ✓ RS percentile 70 or more · RS 78 Trend template - the gate, measured: a modest 21-day edge. | 5/8 | 5 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 1 - basing | |
| CAN SLIM | — C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 277.57 ✗ S more volume on up days than down days (50 sessions) · 0.86x ✗ L RS percentile 80 or more · RS 78 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 1/4 | Weak |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 289.00 ✓ Box bottom confirmed (3 sessions holding) · bottom 182.00 ✗ Close above the box top · close 185.07 ✗ Volume at least 1.5x its 50-day average · 0.4x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 31/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 222.80 ✗ Close above the prior 20-session high · 212.00 ✗ Close below the prior 20-session low · 182.51 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 23.9% — Return on capital (ROCE) · 163.9% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 100/100 | Strong |
| Graham | ✓ Price at or below the Graham number · Graham number 212.76 ✓ P/E 15 or less · P/E 3.8 ✓ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 4.49 ✓ Current ratio 2 or more · 2.47 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 100/100 | Undervalued |
| Piotroski | ✓ Profitable (ROA > 0) ✗ Operating cash flow positive ✓ ROA rising ✗ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✓ Current ratio rising · 2.47 ✓ No new shares issued ✓ Margin rising (net margin) ✓ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 7/9 | Strong |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPARC this stock | -4.6 | -18.6 | +28.1 | +43.0 | -23.9 | -36.8 | 3.8 | 4.49 | 277.4 | 163.9 | — | 0.42 | 4.2 | 6,006 | 1,910 | 1,584 | 48.8 | 1.76 |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ZIMLAB | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |